Fecal calprotectin: A selection tool for small bowel capsule endoscopy in suspected IBD with prior negative bi-directional endoscopy

Scandinavian Journal of Gastroenterology

Volumn 46, Issue 5, 2011, Pages 561-566

  Koulaouzidis, Anastasios ^a   Douglas, Sarah ^a   Rogers, Marie A ^b   Arnott, Ian D ^c   Plevris, John N ^a,b  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

^c WESTERN GENERAL HOSPITAL   (United Kingdom)

Author keywords

Endoscopy general; general; IBD clinical; small intestinal disorders

Indexed keywords

ACETYLSALICYLIC ACID; CALGRANULIN; FECAL CALPROTECTIN; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CAPSULE ENDOSCOPY; CROHN DISEASE; DIAGNOSTIC ACCURACY; ENTERITIS; FECES ANALYSIS; FECES LEVEL; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; PREDICTION; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SMALL BOWEL CAPSULE ENDOSCOPY;

ADOLESCENT; ADULT; AGED, 80 AND OVER; BIOLOGICAL MARKERS; CAPSULE ENDOSCOPY; CROHN DISEASE; FECES; FEMALE; HUMANS; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 79954476797     PISSN: 00365521     EISSN: 15027708     Source Type: Journal    
DOI: 10.3109/00365521.2011.551835     Document Type: Article

References (27)

1. Rubin GP, Hungin AP, Kelly PJ, Ling J. Inflammatory bowel disease: epidemiology and management in an English general practice population.Aliment PharmacolTher 2000;14:1553-9. (Pubitemid 32011728)
2. Tibble JA, Bjarnason I. Non-invasive investigation of inflammatory bowel disease. World J Gastroenterol 2001;7:460-5. (Pubitemid 32782620)
3. Van Limbergen J, Russell RK, Nimmo ER, Satsangi J. The genetics of inflammatory bowel disease. Am J Gastroenterol 2007;102:2820-31. (Pubitemid 350179337)
4. Roth LS, ChandeN, PonichT, RothML, Gregor J. Predictors of disease severity in ulcerative colitis patients from Southwestern Ontario. World J Gastroenterol 2010;16:232-6.
5. Triester SL, Leighton JA, Leontiadis GI, et al. A metaanalysis of the yield of capsule endoscopy compared to other diagnostic modalities in patients with nonstricturing small bowel Crohn's disease. Am J Gastroenterol 2006;101: 954-64. (Pubitemid 43725307)
6. Dionisio PM, Gurudu SR, Leighton JA, et al. Capsule endoscopy has a significantly higher diagnostic yield in patients with suspected and established small-bowel Crohn's disease: a meta-analysis. Am J Gastroenterol 2010;105:1240-8.
7. Ge ZZ, Hu YB, Xiao SD. Capsule endoscopy in diagnosis of small bowel Crohn's disease. World J Gastroenterol 2004;10: 1349-52.
8. Bourreille A, Ignjatovic A, Aabakken L, et al. World Organisation of Digestive Endoscopy (OMED) and the EuropeanCrohn's and Colitis Organisation (ECCO). Role of smallbowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009;41:618-37.
9. Lasson A, Kilander A, Stotzer PO. Diagnostic yield of colonoscopy based on symptoms. Scand J Gastroenterol 2008;43:356-62. (Pubitemid 351238357)
10. Lewis BS, Eisen GM, Friedman S. A pooled analysis to evaluate results of capsule endoscopy trials. Endoscopy 2005; 37:960-5. (Pubitemid 41489265)
11. Doherty GA, Moss AC, Cheifetz AS. Capsule endoscopy in suspected Crohn's disease: "yield" does not equal "diagnosis". Am J Gastroenterol 2010;105:2111.
12. Gisbert JP, McNicholl AG. Questions and answers on the role of faecal calprotectin as a biological marker in inflammatory bowel disease. Dig Liver Dis 2009;41:56-66.
13. Johne B, Kronborg O, Ton HI, Fuglerud P. A new fecal calprotectin test for colorectal neoplasia. Clinical results and comparison with previous method. Scand J Gastroenterol 2001;36:291-6. (Pubitemid 32234579)
14. Tibble JA, Sigthorsson G, Foster R, et al. High prevalence of NSAID enteropathy as shown by a simple faecal test. Gut 1999;45:362-6. (Pubitemid 29400711)
15. von Roon AC, Karamountzos L, Purkayastha S, et al. Diagnostic precision of fecal calprotectin for inflammatory bowel disease and colorectal malignancy. Am J Gastroenterol 2007; 102:803-13. (Pubitemid 46496634)
16. van Rheenen PF, Van de Vijver E, FidlerV. Faecal calprotectin for screening of patients with suspected inflammatory bowel disease: diagnostic meta-analysis. BMJ 2010;341:c3369.
17. Dolwani S, Metzner M, Wassell JJ, Yong A, Hawthorne AB. Diagnostic accuracy of faecal calprotectin estimation in prediction of abnormal small bowel radiology. Aliment Pharmacol Ther 2004;20:615-21. (Pubitemid 39279049)
18. Gralnek IM, Defranchis R, Seidman E, Leighton JA, Legnani P, Lewis BS. Development of a capsule endoscopyscoring index for small bowel mucosal inflammatory change. Aliment Pharmacol Ther 2008;27:146-54. (Pubitemid 350256605)
19. Fagerhol MK, Dale I, Andersson T. A radioimmunoassay for a granulocyte protein as a marker in studies on the turnover of such cells. Bull Eur Physiopathol Respir 1980;16(Suppl): 273-82.
20. Desai D, Faubion WA, Sandborn WJ. Review article: biological activity markers in inflammatory bowel disease. Aliment Pharmacol Ther 2007;25:247-55. (Pubitemid 46115394)
21. Bjerke K, Halstensen TS, Jahnsen F, Pulford K, Brandtzaeg P. Distribution of macrophages and granulocytes expressing L1 protein (calprotectin) in human. Peyer's patches compared with normal ileal lamina propria and mesenteric lymph nodes. Gut 1993;34:1357-63. (Pubitemid 23293619)
22. Jahnsen J, Roseth AG, Aadland E. Measurement of calprotectin in faeces Article in Norwegian. Tidsskr Nor Laegeforen 2009;129:743-5.
23. Logan R. Faecal calprotectin for the diagnosis of inflammatory bowel disease. BMJ 2010;341:c3636.
24. Roseth AG, Schmidt PN, Fagerhol MK. Correlation between faecal excretion of indium-111-labelled granulocytes and calprotectin, a granulocyte marker protein, in patients with inflammatory bowel disease. Scand J Gastroenterol 1999;34:50-4. (Pubitemid 29074787)
25. Poullis A, Irwin AG, Dearing M, et al. Repeat planar white cell scanning to monitor short-term therapy of active inflammatory bowel disease: a methodological study and comparison with clinical scores and novel inflammatory markers. Eur J Gastroenterol Hepatol 2006;18:607-14. (Pubitemid 43804643)
26. Tibble JA, Sigthorsson G, Bridger S, et al. Surrogate markers of intestinal inflammation are predictive of relapse in patientswith inflammatory bowel disease. Gastroenterology 2000; 119:15-22. (Pubitemid 30452574)
27. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Noninvasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMNelastase, CRP and clinical indices. Am J Gastroenterol 2008;103:162-9.